Nyxoah Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Olivier Taelman

Chief executive officer

€807.1k

Total compensation

CEO salary percentage	54.1%
CEO tenure	4.5yrs
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Olivier Taelman's remuneration changed compared to Nyxoah's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-€43m
Dec 31 2023	€807k	€436k	-€43m
Sep 30 2023	n/a	n/a	-€46m
Jun 30 2023	n/a	n/a	-€44m
Mar 31 2023	n/a	n/a	-€36m
Dec 31 2022	€631k	€436k	-€31m
Sep 30 2022	n/a	n/a	-€24m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€29m
Dec 31 2021	€731k	€413k	-€28m
Sep 30 2021	n/a	n/a	-€25m
Jun 30 2021	n/a	n/a	-€21m
Mar 31 2021	n/a	n/a	-€16m
Dec 31 2020	€336k	€263k	-€12m

Compensation vs Market: Olivier's total compensation ($USD874.71K) is about average for companies of similar size in the German market ($USD720.80K).

Compensation vs Earnings: Olivier's compensation has increased whilst the company is unprofitable.

CEO

Olivier Taelman (51 yo)

4.5yrs

Tenure

€807,096

Compensation

Mr. Olivier Taelman serves as a Vice President of Sales Europe at Autonomic Technologies, Inc. Mr. Olivier Taelman is the Chief Executive Officer at Nyxoah S.A. since November 2019 and serves as its Execu...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Robert Taub	Co-Founder & Chairman	14.8yrs	€127.63k	9.84% € 26.4m
Olivier Taelman	CEO & Executive Director	4.5yrs	€807.10k	no data
Loic Moreau	Chief Financial Officer	2.3yrs	€468.69k	0.046% € 123.8k
Bruno Onkelinx	Chief Technology Officer	3.2yrs	no data	no data
Mikaela Kirkwood	Corporate Communication & Investor Relations Manager	no data	no data	no data
An Moonen	General Counsel	3.4yrs	no data	no data
Inge Vanwittenbergh	Global Human Resource Director	1.3yrs	no data	no data
David DeMartino	Chief Strategy Officer	1.3yrs	no data	no data
Remi Renard	Chief of Staff	less than a year	no data	no data
Jeyakumar Subbaroyan	Chief Clinical Officer	less than a year	no data	no data
Francis Kim	Chief Regulatory & Quality Officer	less than a year	no data	no data
Maurits Boon	Chief Medical Officer	less than a year	no data	no data

1.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 5YI's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Robert Taub	Co-Founder & Chairman	14.8yrs	€127.63k	9.84% € 26.4m
Olivier Taelman	CEO & Executive Director	3.7yrs	€807.10k	no data
Kevin Rakin	Independent Non-Executive Director	7.9yrs	€68.59k	0.43% € 1.2m
Jurgen Hambrecht	Independent Non-Executive Director	4.3yrs	€58.50k	4.69% € 12.6m
Daniel Wildman	Independent Non-Executive Director	1.3yrs	€71.28k	no data
Virginia Kirby	Independent Non-Executive Director	1.9yrs	€59.22k	0.019% € 52.0k
Rita Johnson-Mills	Independent Non-Executive Director	2.8yrs	€63.62k	0.019% € 52.0k
Pierre Gianello	Non-Executive Director	6.3yrs	€175.63k	0.040% € 108.2k

4.0yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 5YI's board of directors are considered experienced (4 years average tenure).

Nyxoah Management

Management criteria checks 2/4

Key information

Recent management updates

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Nyxoah S.A. Announces Board Changes

Recent updates

First quarter 2024 earnings released: €0.41 loss per share (vs €0.46 loss in 1Q 2023)

Nyxoah S.A., Annual General Meeting, Jun 12, 2024

Nyxoah SA Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio(R)

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: €0.27 loss per share (vs €0.24 loss in 3Q 2022)

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: €0.45 loss per share (vs €0.19 loss in 2Q 2022)

First quarter 2023 earnings released: €0.46 loss per share (vs €0.26 loss in 1Q 2022)

Nyxoah S.A. Appoints Christoph Eigenmann as Chief Commercial Officer

Full year 2022 earnings released: €1.21 loss per share (vs €1.16 loss in FY 2021)

Nyxoah S.A. to Report Q3, 2023 Results on Nov 08, 2023

Nyxoah S.A. Appoints Daniel Wildman as Independent Director to Its Board of Directors

Third quarter 2022 earnings released: €0.24 loss per share (vs €0.29 loss in 3Q 2021)

Nyxoah S.A. Announces Resignation of Raymond Cohen as Member of the Board of Directors

Second quarter 2022 earnings released: €0.19 loss per share (vs €0.31 loss in 2Q 2021)

Nyxoah S.A. Announces CE Mark Approval for Genio® 2.1

Nyxoah SA Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio in Complete Concentric Collapse Patients

Nyxoah S.A. Announces U.S. Food and Drug Administration Approved the Use of Nyxoah's Next Generation Genio 2.1 System

Nyxoah S.A. Announces Board Changes

Nyxoah S.A. to Report First Half, 2022 Results on Aug 09, 2022

Nyxoah S.A. to Report Fiscal Year 2021 Results on Mar 24, 2022

Nyxoah Announces U.S. FDA Breakthrough Device Designation Granted for the Genio® System for Obstructive Sleep Apnea and Complete Concentric Collapse

Nyxoah Deleted from Other OTC

Nyxoah SA's BETTER SLEEP Trial Reaches its Primary Endpoints

Nyxoah Receives FDA Approval for Full-Body 1.5T and 3T MRI Compatibility for the Genio System to Treat Obstructive Sleep Apnea

Nyxoah S.A. Announces First US Patient Implanted in the DREAM Pivotal IDE Study, with the Genio System for the Treatment of Obstructive Sleep Apnea

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age